REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization

Prior treatment

• Patients participating in any pharmacological or nonpharmacological interventional study starting from 6 months before the index date.

Other illness

• Progressive neurological disease, including degenerative CNS diseases and/or progressive brain tumors;
• Patients with specific syndrome (e.g. LGS and Dravet);

Other

• Patients who meet any of the contraindications to the administration of adjunctive ASMs according to their approved SmPC;
• Patients who started cenobamate within an EAP;
• Pregnancy or lactation;
• Patients without self-judgement ability;
• Patients with substance and alcohol abuse or dependence (except for caffeine and nicotine);

• Male and female patients of any ethnic origin ≥18 years old at index date;
• Patients with a diagnosis of epilepsy with uncontrolled focal-onset seizures despite the previous treatment with from 2 to 5 ASMs who started treatment with cenobamate at index date;
• Patients presenting at least 1 seizure a month in the last 6 months prior to index date;
• Patients with at least 6 months of data coverage in the medical records prior to the index date;
• Patients with at least 12 months of data in the medical records after index date (with a maximum interval between data of 6 months).
• Patients who give the consent to the processing of personal data according to the General Data Protection Regulation (GDPR) and/or other applicable local regulation.